Innovent Biologics, a prominent biopharmaceutical company established in 2011, has announced a strategic partnership with WeComput to enhance its artificial intelligence for drug discovery platform. Innovent specializes in developing and commercializing innovative medicines for various diseases, including oncology, cardiovascular, and autoimmune disorders. With a commitment to providing affordable, high-quality biopharmaceuticals, Innovent has launched ten products and currently has multiple assets in various stages of clinical trials. The collaboration with WeComput aims to leverage advanced AI technology to accelerate the drug discovery and development process, utilizing WeMol, WeComput’s molecular design platform, and NVIDIA's BioNeMo to enhance computational capabilities.
WeComput, founded in 2015, focuses on integrating computational technology to drive innovative drug research and development. By combining their technological strengths, Innovent and WeComput plan to create a comprehensive, AI-driven drug discovery system that improves efficiency, reduces costs, and shortens R&D cycles. This partnership is expected to propel Innovent's research capabilities, facilitating the development of new and innovative treatment options for patients worldwide.
